Clinical Trial Update: Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients [Phase 1]

View source ↗

Summary

Phase 1 safety trial in FAP-positive advanced solid tumors using 68Ga/177Lu-NRT6020 is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• 68Ga/177Lu-NRT6020

Snippet

Sponsor: Chengdu New Radiomedicine Technology Co. LTD. | Conditions: Solid Tumor Malignancy | Phase 1 | Status: RECRUITING